TAK-580 In Gliomas and Other Tumors

  • STATUS
    Recruiting
  • End date
    Dec 31, 2024
  • participants needed
    53
  • sponsor
    Karen D. Wright MD
Updated on 16 July 2021
ejection fraction
measurable disease
tak-580

Summary

This research study is studying a drug TAK-580 (MLN2480) as a possible treatment a low-grade glioma that has not responded to other treatments.

The name of the study drug involved in this study is:

TAK-580 (MLN2480)

Description

This is a Phase I clinical trial. A Phase I clinical trial tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied.

The U.S. Food and Drug Administration (FDA) has not approved TAK-580 as a treatment for any disease.

This is the first time that TAK-580 will be given to children. There is limited experience with TAK-580 in humans.

The purpose of this study is to test the safety TAK-580 in children and adolescent participants with brain tumors. The investigators want to find out what effects, good and/or bad, it has on participants and the participant's brain tumor, and find the dose of TAK-580 that is tolerated by participants without too many side effects to use in Phase II of the study.

Research in the laboratory has shown that TAK-580 may have activity against cancer cells. TAK-580 belongs to a group of drugs called type II BRAF inhibitors. BRAF abnormalities are found in cancer cells. There are no type II BRAF inhibitors approved by the FDA for humans at the time of this study's start. TAK-580 functions by binding the mutant BRAF molecule and causing a conformation change in the molecule thereby blocking the signal that tells the tumor cell to divide.

Details
Condition Low Grade Glioma
Treatment TAK-580
Clinical Study IdentifierNCT03429803
SponsorKaren D. Wright MD
Last Modified on16 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Participants must meet the following criteria on screening examination to be eligible to participate in the study
Phase I
Pediatric patients with radiographically recurrent or radiographically progressive non-hematologic malignancies (Central Nervous System (CNS) or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible with the exception of patients with NF1
Mutational status requires a pathology report, genomic sequencing, or immunohistochemical report of a mutation or activation of the RAS/RAF/MEK/ERK pathway
The remaining criteria include
Patients must be >1 year and <25 years old
Patients must have adequate performance status
Karnofsky 50 for patients 16 years of age (See Appendix A)
Lansky 50 for patients < 16 years of age (See Appendix A)
Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score (See Appendix A)
A patient with low grade glioma who has failed standard therapy
At least 1 measurable lesion that can be reproducibly measured in 2 dimensions
Previous chemotherapy and hormone therapy (excluding physiologic replacement) must be completed at least 4 weeks or 4 half-lives, whichever is longer, prior to administration of TAK-580
Previous immunotherapy/ monoclonal antibody use must be completed at least 4 weeks or 4 half lives, whichever is longer prior to administration of TAK-580. In addition, radiation therapy to the target lesion must be completed at least 6 months prior to administration of TAK-580. All associated toxicity from previous therapies must be resolved to Grade 1 or considered baseline prior to administration of TAK-580
Female patients who
Are postmenopausal for at least 1 year before the screening visit, OR
Are surgically sterile, OR
If they are of childbearing potential, agree to practice 1 effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 90 days (or longer as mandated by local labeling [e.g., United States Protection and Investigations (USPI), Summary of Product Characteristics (SmPC), etc,]) after the last dose of study drug, OR
Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)
Male patients, even if surgically sterilized (i.e., status post-vasectomy)
who
Agree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, OR
Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)
Agree not to donate sperm during the course of this study or within 120 days after receiving their last dose of study drug
Patient must be able to swallow pills whole
Patient, parent, or legal guardian must be able to understand and be willing to provide informed consent
Thyroid function tests must be consistent with stable thyroid function. Patients on a stable dose of thyroid replacement therapy for a suggested minimum of 3 weeks before Cycle 1, Day 1 are eligible
Left ventricular ejection fraction (LVEF) of 50% or greater, as measured by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan, within 28 days before the first dose of TAK-580
Inclusion of Women, Minorities, and Other Underrepresented Populations: This protocol is open to males and females of all races. See inclusion criteria above regarding specific eligibility requirements for female and male patients of child-bearing or child-fathering potential, respectively

Exclusion Criteria

Patients with any of the following characteristics will NOT be
eligible
Patients with clinical progression but without radiographically recurrent or radiographically progressive disease
Patients with NF1
History of any major disease that might interfere with safe protocol participation, as determined by the investigator
Patients with a history or current evidence of central serous retinopathy (CSR), retinal vein occlusion (RVO), or ophthalmopathy present at baseline that would be considered a risk factor for CSR or RVO
Laboratory values
Absolute neutrophil count (ANC) 1000/L
Platelet count 75,000/L (transfusion independent)
Hemoglobin < 9 g/dL (hemoglobin may be supported by transfusion, erythropoietin, or other approved hematopoietic growth factors)
Serum bilirubin 1.5 upper limit of normal (ULN) or 2 ULN if patient is known to have Gilbert's Disease as the only underlying hepatic disorder
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2.5 ULN. AST and ALT 5 ULN for patients with liver metastasis
Serum creatinine 2.0 mg/dL
Current enrollment in any other investigational treatment study
Evidence of current uncontrolled cardiovascular conditions, including but not limited to clinically significant cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction, within the past 6 months
Active hepatitis or human immunodeficiency virus infection
Active bacterial or viral infection
Female patients who are pregnant or currently breastfeeding. Female patients of childbearing potential must have a negative serum pregnancy test prior to enrollment
Major surgery within 28 days of Day 1 (does not include central venous access or shunts)
Inability to comply with study requirements
Refractory nausea and vomiting, malabsorption, or significant bowel or stomach resection that would preclude adequate absorption of TAK-580
Treatment with any of the strong CYP2C inducers within 14 days before the first dose of TAK-580 (see Appendix H)
Treatment with gemfibrozil (strong CYP2C8 inhibitor) within 14 days before the first dose of TAK-580
Other unspecified reasons that, in the opinion of the investigator, make the patient unsuitable for enrollment
Important note: The eligibility criteria listed above are interpreted literally and cannot be waived
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note